Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps

All NewsFebruary 20, 2026

Takeda shares are down slightly on Friday morning after positive Phase 3 Entyvio data show strong remission rates in ulcerative colitis trial.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

What to do for the most luxury travel experience in Perth

Vanguard says inflation is closer to 2% than Tuesday’s CPI suggests

Amazon’s 5-tier rolling storage cart has two drawers with adjustable separators for only $44

Snapchat users are paying up, and Wall Street is missing it

Why Morgan Stanley still believes in Atlassian after the sell-off